Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical News News 22 December 2025 - 23 January 2026

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data hit NEJM

Gilead Sciences shares rose 3.5% to $135.73 Friday, hitting new highs after Phase 3 trial data showed its Trodelvy-Keytruda combo cut the risk of disease progression or death by 35% in metastatic triple-negative breast cancer. Gilead has filed for expanded approval in the U.S. and Europe. Volume reached 8.8 million shares. A Form 144 filing showed executive Deborah Telman plans to sell up to 29,215 shares.
23 January 2026
·······
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares surged 35% Friday after reporting faster enrollment and positive interim results in its ANKTIVA bladder cancer trial. The company also disclosed $113 million in 2025 preliminary revenue and Saudi approval for ANKTIVA in lung cancer. Shares traded at $5.34 by midday with 133 million shares changing hands. Early data from its CD19 CAR-NK cell therapy showed complete responses in Waldenström lymphoma.
16 January 2026
·····
Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

Sarepta stock sinks as Elevidys sales miss, flu delays spill into 2026

New York, Jan 12, 2026, 14:53 EST — Regular session. Sarepta Therapeutics shares dropped roughly 13% to $20.73 in Monday afternoon trading following a disappointing sales forecast for its Duchenne muscular dystrophy gene therapy, Elevidys, in the fourth quarter. This matters because Elevidys has turned into the company’s key swing factor — and a closely watched one at that — for a stock that’s already been tossed around by safety concerns and shifts in treatment protocols over the past year. The timing coincides with the J.P. Morgan Healthcare Conference, where investors usually demand clear guidance and early insights for the
12 January 2026
····
Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

Why Soleno Therapeutics stock is down today: investor alerts revive Vykat XR scrutiny

New York, Jan 9, 2026, 13:28 (EST) — Regular session Soleno Therapeutics shares slid on Friday, extending a choppy stretch for the rare-disease drugmaker. The stock was down 5.6% at $42.95, after touching a low of $42.73, while the SPDR S&P Biotech ETF was up about 1.1%. The move matters now because Soleno’s story still hinges on a young commercial launch and a single product, Vykat XR. Any shift in sentiment around safety, pricing, or patients staying on therapy can hit the stock hard, fast. A Zacks Equity Research industry outlook on Thursday highlighted Soleno alongside Nektar Therapeutics, Rigel Pharmaceuticals,
9 January 2026
···
CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

CG Oncology stock jumps 25% after pulling Phase 3 PIVOT-006 bladder cancer data into 1H 2026

New York, Jan 9, 2026, 11:52 EST — Regular session CG Oncology shares jumped on Friday after the company moved up the expected timing for late-stage trial results in bladder cancer. The stock was up 25.1% at $52.45 by 11:52 EST, versus Thursday’s close of $41.93, after trading between $41.63 and $52.64 on the day as volume topped 4.1 million shares. The faster timetable pulls forward a key catalyst for a biotech still in trials. In this part of the market, investors often trade the calendar as hard as the science. Topline data — the first look at whether a
9 January 2026
····
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward a pivotal, late-stage study. For small drug developers without a marketed product, one clinical readout can reset expectations fast. Pancreatic cancer is a tough proving ground. Survival gains are hard to show, and investors tend to discount early-stage results until
8 January 2026
·····
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny

New York, January 6, 2026, 08:44 EST — Premarket Zenas BioPharma (ZBIO.O) shares were down 5.8% at $15.66 in premarket trading on Tuesday after ending Monday down 51.9% at $16.61. MarketScreener The slide follows a late-stage readout for the company’s lead drug obexelimab in IgG4-related disease (IgG4-RD), a rare immune condition that can inflame and scar organs. Zenas met the main goal, but Wedbush analyst Martin Fan said investors were looking for a stronger effect than the hazard ratio of 0.44, a measure of risk over time where lower is better. Amgen’s Uplizna, the only FDA-approved treatment for IgG4-RD, cut
6 January 2026
·····
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

NEW YORK, December 30, 2025, 05:21 ET — Premarket Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours trading. StockAnalysis+2SEC+2 Breakthrough Therapy Designation is an FDA pathway meant to speed development and review for drugs aimed at serious conditions when early clinical evidence suggests a meaningful step up over available therapies. For traders, it often serves as a
30 December 2025
·····
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas

As of 8:54 a.m. ET in New York on Friday, December 26, 2025, U.S. stock exchanges have not yet opened for the regular session (standard hours are 9:30 a.m. to 4:00 p.m. ET). Nasdaq Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is in focus heading into the post-holiday session after the company delivered an encouraging clinical update for EDG-7500—its investigational therapy for hypertrophic cardiomyopathy (HCM)—that helped drive a sharp rally in the last session before Christmas. PR Newswire Where EWTX stock stands pre-market Market data tracked by MarketBeat shows EWTX closing at $27.38 on December 24 (the last regular session before Christmas
26 December 2025
·····
Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly (LLY) Stock After Hours on Dec. 24, 2025: Christmas Eve Close, GLP‑1 Headlines, and What to Watch Before Markets Reopen

Eli Lilly and Company (NYSE: LLY) wrapped up a holiday-shortened Christmas Eve session with a modest gain — and then drifted slightly lower in thin after-hours trading as investors digested a policy-heavy news cycle around GLP‑1 obesity medicines. With U.S. markets closed on Christmas Day (Thursday, Dec. 25, 2025) and set to reopen Friday (Dec. 26, 2025), today’s late tape is less about big price swings and more about positioning: where Lilly stands in the global obesity market, what Washington’s latest coverage model could mean for pricing and volume, and what catalysts are coming next. AP News Eli Lilly stock
24 December 2025
·····
Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences (GILD) Stock News Today: New Herpes Deal, TrumpRx Pricing Pact, and Fresh Wall Street Forecasts (Dec. 22, 2025)

Gilead Sciences, Inc. (NASDAQ: GILD) opened the holiday-shortened week with a mix of pipeline expansion and policy-driven uncertainty—two themes that can quickly move large-cap biopharma stocks even when overall market volume is lighter than usual. On Monday, December 22, 2025, Gilead announced it has exercised its option to license Assembly Biosciences’ investigational herpes simplex virus (HSV) programs—a move that strengthens Gilead’s long-term antiviral pipeline beyond HIV. The development lands just days after Gilead joined other major drugmakers in a Trump administration “most-favored-nation” drug-pricing agreement tied to tariff relief and direct-to-consumer drug access via TrumpRx.gov. Gilead+2Gilead+2 As of the latest available
22 December 2025
·····
ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

ABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes EffectABIVAXABIVAX Société Anonyme Stock (ABVX) Jumps on Fresh Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Takes Effect

PARIS / NEW YORK — December 22, 2025 — ABIVAX Société Anonyme (Abivax SA) stock is back in the spotlight on Monday after renewed takeover chatter tied to U.S. pharma giant Eli Lilly—arriving the same morning Abivax’s addition to the Nasdaq Biotechnology Index (NBI) becomes effective. The combination is fueling a sharp move in ABVX shares and re-igniting debate about whether 2025’s biotech breakout is now morphing into an M&A (mergers and acquisitions) story. What’s happening with ABIVAX stock today (December 22, 2025) Abivax shares rose sharply in Monday trading as media reports revived speculation that Eli Lilly could be
22 December 2025
··
1 2 3

Stock Market Today

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

Beazley share price: big funds reshuffle stakes as Zurich bid deadline nears

7 February 2026
Beazley shares closed flat at 1,236 pence Friday as BlackRock disclosed a 6.55% stake and Vanguard reported 5.02%. Wellington Management cut its holding below 5%. The disclosures follow Zurich Insurance’s possible takeover offer of up to 1,335 pence per share, with a Feb. 16 deadline for a firm bid.
Go toTop